Takahiro Yokoyama

Dr. Takahiro Yokoyama

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MNMasahito Nakazaki
Masahito Nakazaki
TYTakahiro Yokoyama
Takahiro Yokoyama
KLKaren Lee Lankford
Karen Lee Lankford
RHRyosuke Hirota
Ryosuke Hirota
JKJeffery D Kocsis
Jeffery D Kocsis
OHOsamu Honmou
Osamu Honmou
Spinal cord injury (SCI) disrupts the blood–spinal cord barrier (BSCB) exacerbating damage by allowing harmful substances and immune cells to infiltrate spinal neural tissues from the vasculature. This leads to inflammation, oxidative stress, and impaired axonal regeneration. The BSCB, essential for maintaining spinal cord homeostasis, is structurally similar to the blood–brain barrier. Its restoration is a key therapeutic target for improving outcomes in SCI. Mesenchymal stromal/stem cells (MSCs) and their secreted extracellular vesicles (MSC-EVs) have gained attention for their regenerative, immunomodulatory, and anti-inflammatory properties in promoting BSCB repair. MSCs enhance BSCB integrity by improving endothelial–pericyte association, restoring tight junction proteins, and reducing inflammation. MSC-EVs, which deliver bioactive molecules, replicate many of MSCs’ therapeutic effects, and offer a promising cell-free alternative. Preclinical studies have shown that both MSCs and MSC-EVs can reduce BSCB permeability, promote vascular stability, and support functional recovery. While MSC therapy is advancing in clinical trials, MSC-EV therapies require further optimization in terms of production, dosing, and delivery protocols. Despite these challenges, both therapeutic approaches represent significant potential for treating SCI by targeting BSCB repair and improving patient outcomes.

1 May 2021 in World Neurosurgery
Verified
Journal Article
Closed access
RKRyo Kiyose
Ryo Kiyose
MSMasanori Sasaki
Masanori Sasaki
YKYuko Kataoka-Sasaki
Yuko Kataoka-Sasaki
MNMasahito Nakazaki
Masahito Nakazaki
HNHiroshi Nagahama
Hiroshi Nagahama
OHOsamu Honmou
Osamu Honmou

6 July 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
SOShinichi Oka
Shinichi Oka
TYTomohiro Yamaki
Tomohiro Yamaki
MSMasanori Sasaki
Masanori Sasaki
RURYO UKAI
RYO UKAI
MTMitsuhiro Takemura
Mitsuhiro Takemura
OHOsamu Honmou
Osamu Honmou
Background: Brain injuries resulting from motor vehicle accidents and falls, as well as hypoxic insults and other conditions, are one of the leading causes of disability and death in the world. Current treatments are limited but include continuous rehabilitation, especially for chronic brain injury. Recent studies have demonstrated that the intravenous infusion of mesenchymal stem cells (MSCs) has therapeutic efficacy for several neurological diseases, including stroke and spinal cord injury. Objective: The objective of our investigator-initiated clinical trial is to assess the safety and potential efficacy of the intravenous infusion of autoserum-expanded autologous MSCs for patients with chronic brain injury. Methods: The (phase 2) trial will be a single-arm, open-label trial with the primary objective of confirming the safety and efficacy of autoserum-expanded autologous MSCs (STR-01; produced under good manufacturing practices) when administered to patients with chronic brain injury. The estimated number of enrolled participants is 6 to 20 patients with a modified Rankin Scale grade of 3 to 5. The assessment of safety and the proportion of cases in which the modified Rankin Scale grade improves by 1 point or more at 180 days after the injection of STR-01 will be performed after MSC infusion. Results: We received approval for our clinical trial from the Japanese Pharmaceuticals and Medical Devices Agency on December 12, 2017. The trial will be completed on June 11, 2023. The registration term is 5 years. The recruitment of the patients for this trial started on April 20, 2018, at Sapporo Medical University Hospital in Japan. Conclusions: Our phase 2 study will aim to address the safety and efficacy of the intravenous infusion of MSCs for patients with chronic brain injury. The use of STR-01 has been performed for patients with cerebral infarction and spinal cord injury, providing encouraging results. The potential therapeutic efficacy of the systemic administration of autoserum-expanded autologous MSCs for chronic brain injury should be evaluated, given its safety and promising results for stroke and spinal cord injury. Trial Registration: Japan Medical Association Center for Clinical Trials JMA-IIA00333; https://tinyurl.com/nzkdfnbc International Registered Report Identifier (IRRID): DERR1-10.2196/37898

20 November 2023 in Interdisciplinary Neurosurgery
Verified
Journal Article
Open access
TYTomohiro Yamaki
Tomohiro Yamaki
SOShinichi Oka
Shinichi Oka
SISatoshi Iyama
Satoshi Iyama
MSMasanori Sasaki
Masanori Sasaki
RORie Onodera
Rie Onodera
OHOsamu Honmou
Osamu Honmou

11 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RHRyosuke Hirota
Ryosuke Hirota
MSMasanori Sasaki
Masanori Sasaki
SISatoshi Iyama
Satoshi Iyama
KKKota Kurihara
Kota Kurihara
RFRyunosuke Fukushi
Ryunosuke Fukushi
OHOsamu Honmou
Osamu Honmou
Objective: The safety, feasibility, and potential functional improvement following the intravenous infusion of mesenchymal stem cells (MSCs) were investigated in patients with chronic severe spinal cord injury (SCI). Methods: The intravenous infusion of autologous MSCs cultured in auto-serum under Good Manufacturing Practices (GMP) was administered to seven patients with chronic SCI (ranging from 1.3 years to 27 years after the onset of SCI). In addition to evaluating feasibility and safety, neurological function was evaluated using the American Spinal Injury Association Impairment Scale (AIS), International Standards for Neurological Classification of Spinal Cord Injury (ISCSCI-92), and Spinal Cord Independence Measure III (SCIM-III). Results: No serious adverse events occurred. Neither CNS tumors, abnormal cell growth, nor neurological deterioration occurred in any patients. While this initial case series was not blinded, significant functional improvements and increased quality of life (QOL) were observed at 90 and 180 days post-MSC infusion compared to pre-infusion status. One patient who had an AIS grade C improved to grade D within six months after MSC infusion. Conclusions: This case series suggests that the intravenous infusion of autologous MSCs is a safe and feasible therapeutic approach for chronic SCI patients. Furthermore, our data showed significant functional improvements and better QOL after MSC infusion in patients with chronic SCI. A blind large-scale study will be necessary to fully evaluate this possibility.

9 December 2023 in Brain Research
Verified
Journal Article
Closed access
TYTatsuro Yamashita
Tatsuro Yamashita
MSMasanori Sasaki
Masanori Sasaki
YSYuichi Sasaki
Yuichi Sasaki
HNHiroshi Nagahama
Hiroshi Nagahama
SOShinichi Oka
Shinichi Oka
OHOsamu Honmou
Osamu Honmou